Phtivazide MS (Phthivazid MS)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substancePhthivazidePhthivazide
Similar drugsTo uncover
  • Phthivazide
    pills inwards 
    FARMASINTEZ, JSC (Irkutsk)     Russia
  • Phthivazide
    pills inwards 
    AVEKSIMA, JSC     Russia
  • Phthivazide
    pills inwards 
    ROSFARM, LLC     Russia
  • Phthivazide
    pills inwards 
    UZOLE-SIBERIAN CHEMICAL PLANT, OJSC     Russia
  • Phtivazide MS
    pills inwards 
    MEDISORB, CJSC     Russia
    • Dosage form: & nbsppills
    Composition:

    1 tablet contains:

    active substance: ftyvazid 0.5 g;

    Excipients: potato starch, povidone (polyvinylpyrrolidone), calcium stearate.

    Description:

    Tablets of light yellow or yellow color, flat-cylindrical form with a weak smell of vanillin.

    Pharmacotherapeutic group:Anti-tuberculosis drug.
    ATX: & nbsp

    J.04.A.C   Derivatives of isonicotinic acid hydrazide

    Pharmacodynamics:

    Phthivazide - anti-tuberculosis drug, isonicotinic acid hydrazide derivative (GINC). Has a pronounced selective activity against mycobacteria tuberculosis. It causes damage to the membrane of mycobacteria, inhibits metabolic and oxidative processes, inhibits the synthesis of nucleic acids, acts on mycobacteria both inside the cell and outside it. Slowly absorbed from the digestive tract. Penetrates through the placental barrier and into breast milk.

    Indications:

    Treatment of active tuberculosis of all forms and localizations in adults and children.

    Contraindications:

    -increased sensitivity to ftivazidu;

    -Birth, lactation;

    - angina pectoris; decompensated heart defects;

    -organic diseases of the central nervous system;

    - kidney disease of non-tuberculous nature, as well as with impaired excretory function;

    - liver disease;

    -alcoholism;

    -Children's age is up to three years.

    Dosing and Administration:

    Is taken internally.

    Adults - 500 mg 2-3 times / day. Higher doses for adults: single dose - 1 g, daily - 2 g. Children from three years - at the rate of 30-40 mg / kg / day (maximum daily dose - 1.5 g) in 3 divided doses. In case of tuberculous lupus - 250-300 mg 3-4 times / day. On the course - 40-60 g. If necessary, the course of treatment is repeated 2-3 times with a monthly break.

    Side effects:

    From the skin: skin allergic reactions.

    From the cardiovascular system: pain in the heart and epigastrium.

    From the central nervous system: increased fatigue, headache, dizziness; euphoria, sleep deterioration, in rare cases - the development of psychosis, memory disorders, peripheral neuritis and optic neuritis. In patients with epilepsy, convulsive seizures may increase.

    From the side of the digestive tract: decreased appetite, gastralgia, nausea, vomiting, dry mouth, drug-induced hepatitis.

    From the endocrine system: in men - gynecomastia, in women-menorrhagia.

    Other: increased bleeding, arthralgia.

    Adverse events occur with a reduced dose or a temporary break in taking the drug.

    Interaction:

    With simultaneous application flvivazide strengthens side effects of alcohol, paracetamol, benzodiazpines (including carbamazpine) and hepatotoxic drugs.

    With simultaneous application of the drug strengthens the effect of anticoagulants and antiaggregants.

    With simultaneous application reduces the action of mineralocorticoids and glucocorticoids.

    Simultaneous reception of antacids slows the absorption of ftyvazid.

    Special instructions:

    During the period of treatment, periodic examination of the fundus is necessary. To prevent the development of neuritis, concomitantly with the drug, vitamins B1 and B6. The drug can be used to treat patients with increased sensitivity to isoniazid. The maximum efficiency is manifested with "fresh", acute processes.

    Form release / dosage:

    Tablets of 0.5 g.


    Packaging:

    For 25, 50, 100 tablets in polymer cans.

    For 10 tablets in a contiguous cell-free or contiguous cell package.

    By 3, 5, 10 contour mesh or cell-free packages or 1 jar in a bundle.

    Storage conditions:

    List B. In a dry, dark place, place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    4 years.

    Do not use the product after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:P N001393 / 01
    Date of registration:05.12.2008
    The owner of the registration certificate:MEDISORB, CJSC MEDISORB, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp29.10.2015
    Illustrated instructions
      Instructions
      Up